Santen Pharmaceutical Co (Santen Pharmaceutical Co) Additional Paid-In Capital : $66 Mil(As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Santen Pharmaceutical Co Additional Paid-In Capital?

Santen Pharmaceutical Co's quarterly additional paid-in capital declined from Jun. 2023 ($70 Mil) to Sep. 2023 ($63 Mil) but then increased from Sep. 2023 ($63 Mil) to Dec. 2023 ($66 Mil).

Santen Pharmaceutical Co's annual additional paid-in capital declined from Mar. 2021 ($82 Mil) to Mar. 2022 ($79 Mil) and declined from Mar. 2022 ($79 Mil) to Mar. 2023 ($73 Mil).

Santen Pharmaceutical Co Additional Paid-In Capital Historical Data

The historical data trend for Santen Pharmaceutical Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santen Pharmaceutical Co Additional Paid-In Capital Chart

Santen Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Additional Paid-In Capital

Get a 7-Day Free Trial

77.93

81.23

82.37

79.02

73.24

Santen Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															71.22	73.24	70.42	63.40	66.04

Santen Pharmaceutical Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Santen Pharmaceutical Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Santen Pharmaceutical Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (OTCPK:SNPHY) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

SNPHF:USA 4536:Japan SZD:Germany

Address

Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552

Website

http://www.santen.co.jp

Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Headlines

From GuruFocus

Matthews Japan Fund Comments on Santen Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood • 04-23-2020

Matthews Japan Fund 1st-Quarter Commentary

By Sydnee Gatewood Sydnee Gatewood • 04-23-2020